Montana Legal THCa Rick Simpson Oil by OilWell Cannabis, Houston, Texas—16,590mg 7-Cannabinoid RSO Sublingual Formula: 553mg/mL with 1,500mg Patient-Controlled THCa for Up to 1,405mg Activated Delta-9 THC, ABC13-Featured, Texas DSHS Licensed, Bentley’s 10-Year Miracle Legacy, Baylor College of Medicine-Connected Founder, Farm Bill-Compliant Nationwide Shipping

Rick Simpson Oil in Montana: The Complete Guide by OilWell Cannabis

About Rick Simpson and Traditional Rick Simpson Oil

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker — a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him. For Montanans who’ve faced similar frustrations with conventional medicine, especially those in rural areas where specialist care can be hours away, this story resonates deeply.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. He reported that prescribed medications either failed to help or made his condition worse. When he asked his physician to support cannabis use, the request was refused. Many Montanans who’ve turned to cannabis after workplace injuries — particularly those in our state’s construction, agriculture, and energy sectors — know this pattern all too well.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 study at the Medical College of Virginia, where THC reportedly slowed or shrank tumors in mice. That study was originally intended to demonstrate harm but became a foundational reference point for Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Simpson claimed three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification, biopsy confirmation, or clinical follow-up has been published in any peer-reviewed source. This remains personal testimony, not medical evidence, but it became the origin story of Rick Simpson Oil.

The Crusade — Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community, charging nothing. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, and insomnia — the same conditions that drive Montanans to search for alternatives today.

His story reached global audiences through the 2005 documentary Run From The Cure, which became foundational in cannabis communities. For many, it was their first introduction to concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The RCMP raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, he eventually left Canada for Europe, continuing his advocacy from Croatia and later the Netherlands.

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his primary platform. Throughout his career, Simpson maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge.

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. It helps explain RSO’s cultural significance, even as we commit to evidence-based evaluation.

The Traditional RSO Protocol — Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core recommendation was a structured oral protocol delivering 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous conditions.

Goal

Consume 60 grams of high-THC cannabis oil over about 90 days. Simpson considered this the minimum necessary for serious cancer treatment.

Titration Schedule

• Week 1: Begin with a dose the size of half a grain of rice — roughly 10-15 mg of oil — taken three times daily. Total daily intake: approximately 30-45 mg.
• Weeks 2-5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period, target approximately 1 gram (1,000 mg) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day and continue until the full 60 grams are consumed.

Administration Methods

• Primary — oral: Place the dose under the tongue (sublingual) or swallow. Simpson considered oral ingestion most important for systemic absorption.
• Secondary — topical: For skin cancers and external lesions, apply oil directly to the affected area, cover with a bandage, and change every three to four days.
• Not recommended as primary — inhalation: Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that oral dosing was necessary for sustained, high-dose exposure.

Tolerance and Psychoactive Effects

• Simpson maintained that patients develop significant tolerance to THC’s psychoactive effects within 3-4 weeks.
• He considered euphoric, sedating, or disorienting effects minor and temporary, urging patients not to let the high discourage continuation.
• He recommended initial nighttime dosing to sleep through the most intense psychoactive effects.
• He advised against driving or operating machinery during titration and suggested informing family members about what to expect.

Post-Protocol Maintenance

After completing the 60-gram course, Simpson recommended a maintenance dose of 1-2 grams of oil per month indefinitely, considering it important for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson also advocated reducing sugar intake, avoiding processed foods, and improving overall nutrition, though his dietary advice was secondary and general compared to his detailed oil protocol.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, or formal research. Critical points:

• No controlled trial validation. No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming 60-90% THC, this translates to 600-900 mg of delta-9 THC per day — far exceeding anything studied in controlled clinical settings. For context, FDA-approved dronabinol is typically dosed at 2.5-20 mg per day.
• Real risks at these doses. Consuming 600-900 mg of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the research literature.
• Oncology context. Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary cancer treatment — potentially in place of proven therapies — introduces harm beyond the oil itself.

What Is Traditional Rick Simpson Oil — The Product

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined by his method and materials, not lab specifications or regulatory standards.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa strains for cancer treatment. He grew his own cannabis or sourced from trusted growers. There was no strain standardization — starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid or Varsol. He later endorsed 99% isopropyl alcohol as an acceptable alternative. He explicitly warned against butane or acetone. Neither naphtha nor isopropyl alcohol is food-grade, creating significant safety concerns.

Extraction Process

1. Dry or semi-dry cannabis plant material placed in a container (typically a bucket).
2. Material covered with solvent and agitated for several minutes to dissolve cannabinoids.
3. Solvent poured off through a filter (cheesecloth or similar mesh) into a separate vessel.
4. Process repeated a second time with fresh solvent.
5. Combined solvent washes placed in a rice cooker or similar open-vessel heating device.
6. Solvent evaporated at relatively low heat. Simpson recommended a rice cooker because it maintains temperature that evaporates solvent without exceeding cannabinoid degradation thresholds. However, this temperature was still high enough to decarboxylate THCa into THC and destroy most volatile terpenes.
7. As solvent evaporated, thick, dark oil remained at the bottom.
8. Final oil transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was extremely dark — nearly black — thick, viscous, tar-like oil with strong cannabis odor and possible solvent-residual smell depending on purge thoroughness. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. Heat during solvent evaporation converted essentially all THCa to delta-9 THC. Traditional RSO was an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. The profile was entirely determined by genetics and growing conditions.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from 60-90% total THC by weight, though this was never lab-verified in traditional production.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes) and high-heat evaporation (which volatilizes terpenes at temperatures well below cannabinoid degradation) meant traditional RSO was effectively stripped of terpene content.

Standardization and Testing

None. Every batch was different because it depended entirely on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic or carcinogenic compounds. Incomplete solvent purging — difficult to verify without lab testing — leaves potentially harmful residues. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s Claims vs. The Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated RSO could cure cancer — including terminal cases — and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What The Preclinical Literature Shows

The preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines.
• Animal model studies show some tumor-growth inhibition in mice and rats treated with cannabinoids.

What The Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro/animal results and human clinical outcomes is vast and well-documented across all oncology research.
• No human clinical trial has demonstrated RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced results supporting cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as cancer treatment.
• The FDA has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS — not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious biomedical research area when the world was ignoring or suppressing that conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine.

The Legacy of Rick Simpson and The Evolution of Modern RSO

The term RSO is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in syringe format.

Simpson has been critical of commercial products that use the RSO name while departing from his original method and philosophy. He gave his oil away for free and taught people to make it rather than buy from companies. The modern cannabis industry has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective.

What is not in dispute is that modern RSO has evolved substantially, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No — fully decarboxylated by heat	Yes — THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge From Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the tradition but depart deliberately:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. OilWell includes live terpenes at 5% with a specific seven-terpene profile because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation remains developing.

• THCa as separate ingredient. Traditional RSO fully decarboxylated everything. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC.

• Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while distributing remaining cannabinoid content across CBD, CBG, delta-8 THC, CBN, and CBC — reflecting the broader cannabinoid research landscape.

• Product format innovation. Simpson envisioned only one format: oral oil from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic or carcinogenic compounds. Incomplete solvent purging — difficult to verify without analytical chemistry equipment — leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker — typically sustained at or near solvent boiling points (60-80°C for naphtha, ~82°C for isopropyl alcohol) — converted essentially all THCa to delta-9 THC. This meant acidic cannabinoids abundant in raw cannabis (THCa, CBDa, CBGa) were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce psychoactive effects associated with THC, but interpretation depends on route, temperature, processing, and storage because THCa can convert to THC under heating or over time.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes volatilize at temperatures between 21-157°C, with many abundant terpenes (myrcene, limonene, pinene) boiling below 180°C. Traditional RSO production destroyed terpenes in two ways: first, by dissolving them into solvent wash along with cannabinoids; second, by evaporating them during high-heat solvent removal.

This meant traditional RSO was essentially a cannabinoid-only product, despite being derived from terpene-rich plant material. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile. The entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing — it is a description of the environment.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to modern cannabinoid science standards.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison with modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Key differences:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Terpene presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%.
• Delta-9 THC exposure: Simpson’s protocol at peak delivered approximately 600-900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL).

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence and responsible titration principles accounting for each cannabinoid’s safety profile. This section does not provide specific dosing recommendations — that would require its own development process incorporating safety considerations documented throughout this file.

About OilWell Cannabis and The OilWell RSO Formula

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas — right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts — vibrant culture and thriving retail, yet deeply affected by poverty and limited opportunities outside retail and healthcare. Reynosa, an industrial hub plagued by violence and cartel activity, makes it a harsh environment.

Colin’s childhood was marked by exposure to both opportunities and challenges of border life. Early on, he learned to hustle, taking on risky work transporting items across the border. Those experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison because of associated dangers. He faced every form of violence imaginable, both in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths like selling harder substances. Instead, he focused on cannabis, seeing it as a safer, more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — defines OilWell’s approach.

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss. Bentley was a fighter, just like him. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything.

A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. He’d never explored therapeutic applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — notoriously difficult and dangerous — using the cannabinoid knowledge he developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis Colin first discovered through saving Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston — Houston’s number-one news source — featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced — they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. While Montana maintains its own cannabis regulations, this product is accessible under the federal Farm Bill framework, bringing legitimate RSO access to Montanans regardless of medical program participation.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. For Montana residents who work in demanding environments — whether on ranches, in mines, or in healthcare — this means daytime functional use without impairment, with the option for full-potency relief when needed.

3. Open-source formulas. OilWell publishes complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the product can source ingredients and make their own version. For Montanans in economically challenged areas, particularly rural communities where $129.99 may be prohibitive, this open-source approach ensures no one is shut out from the information.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most states, including Montana.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

The practical significance is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as non-psychoactive anti-inflammatory (used raw) or as full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, enabling shipping to Montana and other jurisdictions where hemp-derived products with <0.3% delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. Montana customers should verify state law compliance before decarboxylating THCa.

Open-Source Formulas — Why OilWell Publishes Everything

OilWell publishes complete RSO formulas publicly — every cannabinoid, every milligram amount, every percentage — in documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this document.

The rationale is straightforward: if someone cannot afford OilWell’s products — $129.99 for sublingual oil, $49.99 for vape cartridge — they can see exactly what the formula contains, source individual cannabinoid distillates and isolates, and make their own version. The formulas detailed later are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: sell a professionally manufactured, lab-tested, standardized product for those who want it, and publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy didn’t start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets — The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs of pet; consult veterinarian)

Instructions:

1. Mix turmeric and water. In a saucepan, combine turmeric powder and water, stirring over low heat continuously until it forms a thick paste (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Once thick paste forms, add coconut oil and freshly ground black pepper. Stir until thoroughly mixed.
3. Cool and store. Allow paste to cool, then transfer to jar with lid. Store in refrigerator for up to two weeks.
4. Dosage. Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and gradually increase as needed.

Serving suggestion: Mix small amount of golden paste with pet’s food once or twice daily. Monitor pet for changes and consult veterinarian if concerns arise. Always consult veterinarian before starting any new supplement regimen.

This recipe — published for free, years before RSO formulas were open-sourced — demonstrates the pattern is consistent. Colin gave away the formula that saved Bentley before giving away the formula for people. The open-source ethos is not a marketing strategy; it is foundational behavior.

The Decarboxylation Choice — Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa to THC, leaving patients with no choice about psychoactivity — the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1 — Raw, no heat. All 1,500 milligrams stays as THCa — completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment — crucial for Montana residents who operate heavy equipment, work long shifts, or need functional clarity.

Option 2 — Fully activated, home decarboxylation. Heating oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa to approximately 1,315 milligrams of delta-9 THC. Combined with existing 90 milligrams, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100% legally, because decarboxylation occurs at customer’s discretion after purchase. Customer may also transfer controlled portion from original bottle into second oven-safe container, decarboxylating only intended use amount while preserving remainder in raw THCa form.

Option 3 — Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

Conversion chemistry: THCa has molecular weight of 358.47 g/mol. Conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in customer’s hands — aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing it through actual product chemistry rather than one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not traditional extraction product. It is formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents present in finished product.

This approach eliminates residual solvent risk — one of the most significant safety concerns with traditional RSO production.

Product uses organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating cannabinoid absorption through sublingual tissue and providing neutral taste profile — significant improvement over tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces range of cannabinoid products, each developed from formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. Asshole Peach is carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for ability to relieve pain and PTSD symptoms without being overly aggressive. For Montana’s veteran community — significant in cities like Billings, Great Falls, and Missoula, and across rural areas — this product has particular relevance.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Formula also available in vape form for quick relief — Colin personally uses vape to manage his insomnia and severe PTSD on ongoing basis.

Custom creations — OilWell offers custom-made products tailored to specific customer needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats

OilWell offers RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula (no separate delta-9 THC listed — auto-decarbs at vaping temp)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison — OilWell RSO vs. Alternatives

OilWell RSO vs. Texas TCUP Dispensary RSO

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No — always fully psychoactive	Yes — THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping to Montana
Farm Bill compliant	No — state medical cannabis program	Yes — <0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes — via THCa decarboxylation and delta-8 THC
Approximate price	$40-$50	$129.99

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea/vomiting evidence, CBD anxiolytic buffering

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL, delivers 50 mg CBN — dosage level investigated in 2024 sleep literature
• At 1.0 mL, delivers 25 mg CBN — above 20 mg threshold associated with reduced sleep disturbance
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Global Accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally, including to Montana.

Houston same-day delivery

Zone	Coverage	Delivery fee	Typical turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, etc.)	FREE	2-4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2-4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3-5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4-6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20-$25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center — the world’s largest medical complex with over 10 million patient visits annually — reflects OilWell’s commitment to accessibility.

Nationwide shipping to Montana

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available
• Delivery available to all Montana addresses from Billings to Missoula, Bozeman to Kalispell, and every rural route in between

International shipping
OilWell ships internationally and has delivered to multiple countries across continents. The THCa legal framework makes this possible: because the product contains <0.3% delta-9 THC at point of sale, it meets hemp product definition under 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs
• Minimum flat-fee shipping applies; excessive costs billed to customer
• Customer responsible for verifying legality in their jurisdiction and accepts all customs/legal risk
• Contact: (832) 416-2816 or [email protected]

Montana-specific access: For Montanans, this means legitimate, lab-tested, multi-cannabinoid RSO can arrive at your doorstep regardless of local dispensary availability. Whether you’re in a city with medical cannabis access or a rural area hours from the nearest provider, OilWell’s shipping infrastructure ensures you can obtain the same clinical-strength formula available in Houston.

OilWell’s PANDEM1C SEO technology — proprietary system with 14 million distinct geopolitical locations in database and over 300 AI models — drives organic search visibility across six continents, making OilWell products discoverable to Montana patients searching for RSO.

How The OilWell Formulas Connect to The Evidence

Every cannabinoid in OilWell’s formula — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — has its own evidence profile in the GENERAL KNOWLEDGE section. Every terpene — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — is covered with preclinical and review-level evidence.

The formulas published later are anchored to per-compound evidence summaries explaining what is well-supported by human clinical data, what is emerging from review/preclinical literature, and what is overstated. Where OilWell’s RSO guide makes specific research claims about individual cannabinoids or terpenes, this document provides source evaluation context — the same peer-reviewed citations, evidence-tier assessments, and cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from same evidence standards applied to broader cannabinoid field. That is intentional. OilWell’s position — as stated by Colin Valencia in 2019 — is that people deserve best possible version of information so they can give it fair shot and decide for themselves whether it is right or wrong for them. This document is research foundation for that position.

Media Recognition and Community Impact

Colin Valencia — Houston’s Go-To Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) — ABC affiliate serving America’s fourth-largest city — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth during same period.

The features document consistent pattern. When ABC13 needed to explain new cannabis product, it called Colin. When state agency reversed course on Delta-8 legality overnight, it called Colin. When sitting president announced marijuana pardons and station needed someone who personally lived with cannabis conviction to put it in context, it called Colin. When station wanted to tell story of growing industry on 4/20, it was Colin’s hemp field and voice that anchored report.

What follows is complete, chronological record of each feature — every quote preserved exactly as published, every contextual detail documented, every connection to broader OilWell story and mission noted.

Feature: Texas CBD Businesses Booming as Industry Continues to Evolve — September 15, 2019

Source: ABC13 Houston (KTRK)
Headline: “Texas CBD businesses booming as industry continues to evolve”
Reporter: Tom Abrahams
Published: Sunday, September 15, 2019

This earliest documented ABC13 feature is origin point of foundational philosophy driving everything in this document.

Full Article Content

HOUSTON, Texas (KTRK) — You can spot the signs in almost any neighborhood. CBD has turned into a booming business over the past few months, with entrepreneurs pitching the product for every member of the family, even the pets.

Amanda Field owns Republic Aerial Yoga on Houston Avenue in downtown. Her clients visit her studio for their health, to educate themselves, and to lessen their aches and pains.

“I’ve had people tell me that they’ve come to two classes and their back pain is gone.”
— Amanda Field, Republic Aerial Yoga owner

But for Field, it’s not just about yoga. Many of her clients combine the exercise with cannabidiol, a hemp-based product better known as CBD.

“It partners so well with yoga.”
— Amanda Field

Krystal Burns is one of those clients. She said she injured her back in an accident and had surgery. She said she was in constant pain and said doctors wanted to prescribe her opioids. Burns refused, and after learning about CBD from Field, she says she’s now a believer.

“I wouldn’t be able to function without it. It easily relaxes my muscles, it helps me sleep. I don’t have to worry about addiction.”
— Krystal Burns, CBD user and yoga client

Jim Bagley is another believer. He owns Linear Salon in the Heights. He says he and his wife use CBD and sell it in their shop.

“I was having trouble sleeping, restless in the mid-morning probably. I truly feel that there is benefits to it. I hope it’s not a trend. I think that the benefits I’ve received personally, hopefully I’ll be able to get my clients to enjoy the same benefits I’ve received.”
— Jim Bagley, Linear Salon owner

CBD use was in a legal, gray area in Texas until House Bill 1325, which Gov. Greg Abbott signed into law in June. The bill changed the legal definition of marijuana and hemp production in Texas. As a result, CBD as a business is booming. The product, however, cannot have .3 percent of THC, the chemical that makes you high.

That past summer, four local district attorneys announced they would not file criminal cases involving marijuana or cannabis unless testing proved the THC concentration was higher than .3 percent.

Dorral Marsenburg sells his Booman cannabis in a smokable form and says the industry is in its infancy in Texas.

“In a typical week, I’ll go through a half a pound selling grams. I say two years from now, it’ll be a multi-billion dollar operation. I honestly believe that because it’s 100 percent legal, and besides the THC, it’s healthy for you also.”
— Dorral Marsenburg, Booman cannabis

Colin Valencia, who runs OilWell CBD, a local wholesaler, says it’s an evolving industry.

“It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”
— Colin Valencia, OilWell CBD

The FDA is still examining the actual health benefits and ways to regulate the content of cannabis products. In May, it held its first ever CBD hearings and states it is committed to sound, science-based policy.

That Colin quote — from 2019, years before formulas in this document were published — is seed of everything OilWell would become. The open-source formula publication, evidence-based research documentation, refusal to make unsupported claims: it all traces back to this principle.

Feature: Entrepreneur Creates Direct-to-Consumer Business Ahead of Marijuana Decriminalization Efforts — March 22, 2021

Source: ABC13 Houston (KTRK)
Headline: “Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts”
Reporter: Tom Abrahams
Published: Monday, March 22, 2021

Full Article Content

HOUSTON, Texas (KTRK) — The proof is evident that decriminalizing cannabis doesn’t increase crime rates, according to Senate Majority Leader Chuck Schumer. It’s a basis as to why there is a renewed push to decriminalize cannabis at the national level.

One entrepreneur is already coming up with a unique way to get cannabis directly to the customer.

It’s not a taco truck. In fact, Jonathan Pina’s concept for High Maintenance Edibles is not like any other mobile vendor you’ve likely seen.

“We partner with private companies, bars restaurants, parking lot owners and we show up at places around Houston and provide our products.”
— Jonathan Pina, High Maintenance Edibles

His concept got a lift from Oil Well. A company that specializes in hemp based products legal in Texas and run by owner Colin Valencia. He said the tide is turning and more and more people accept legitimate uses for cannabis based products. The stigma is slowly disappearing.

“People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”
— OilWell CBD’s Colin Valencia

It’s getting a step closer to both decriminalization and legalization. While Texas may be far from legal recreational use, Congress may make its own move.

This week, Schumer and Senators Corey Booker of New Jersey and Ron Wyden of Oregon announced forthcoming legislation on Capitol Hill.

“When states decriminalized or legalized, all the horrible stories that people said crime rates would go up, people’s drug use would go up, never materialized.”
— Senator Chuck Schumer

The three of them cited the failed war on drugs, that veterans and people of color are disproportionately punished for use with excessive fines or jail time. There are already 15 states that have passed ballot measures or have laws allowing recreational use.

“If people want to use it and it doesn’t do harm, just like Oregon showed, let them do it.”
— Senator Chuck Schumer

For those in the business and on its forefront in Texas, entrepreneurs like Pina believe it’s long overdue. But in Austin, they are not there yet. Despite loosening restrictions and a spate of bills this session, full legalization is not as likely as it might be in Washington.

Tom Abrahams returned to OilWell for this feature, establishing Colin’s role not just as business operator but as ecosystem builder who helped other entrepreneurs like Jonathan Pina enter legal cannabis space. Colin’s therapy quote — “pain comes in a lot of different forms” — went deeper than any prior interview into therapeutic dimension, and national decriminalization context positioned OilWell at intersection of Texas innovation and federal momentum.

Feature: What is Delta 8 THC and Why is it Considered Legal Weed in Texas — May 24, 2021

Source: ABC13 Houston (KTRK)
Headline: “What is Delta 8 THC and why is it considered ‘legal weed’ in Texas?”
Reporter: Steve Campion
Published: Monday, May 24, 2021

This investigative feature by Steve Campion became one of most widely referenced ABC13 cannabis segments.

Full Article Content

A lush green plant is creating buzz in Texas as the cannabis industry is booming, despite federal and state law banning marijuana.

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta 9 THC. That’s the THC typically found in pot which gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta 8 THC. They’re making products including edibles, tinctures, and smokables with it. Delta 8 THC isn’t as strong as Delta 9 THC.

You’ll likely spot the Delta 8 products in stores around the Greater Houston like at HydroShack Hydroponics on West 20th Street in The Heights which sells Oilwell Cannabis products.

“Demand is like this,” . “People are grateful that we’re here and selling it. Very grateful. That’s the feeling I get.”
— Chris Powers, owner of HydroShack Hydroponics

Colin Valencia with Oilwell said the products offer therapeutic benefits at affordable prices. Valencia remained unabashed by his enthusiasm for them. He offered a pretty blunt explanation about how some might use Delta 8.

Steve Campion (ABC13): “Why would someone want to smoke that?”

Colin Valencia: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

“Delta 8 hasn’t been looked at, so we just don’t know. We’re gathering data now, so the more people who use, the more information we’ll have. You probably don’t want to be a guinea pig just yet. We know Delta 9 THC is habit forming. Delta 8 THC is likely to have that property as well. If you’re using it, you may find it’s harder to stop than you thought.”
— Dr. Michael Weaver, UTHealth/UT Physicians addictions specialist

ABC13 then asked him if he would advise anyone to take it.

“I think there is not enough information to say it’s good to try. The safest thing I can say is we don’t know enough about it to make a recommendation. Don’t try it until we know more.”
— Dr. Michael Weaver

Experts said using Delta 8 THC will likely lead to failed drug tests for employees.

Heather Fazio with Texans for Responsible Marijuana Policy told ABC13 some lawmakers already want to ban Delta 8 products in the state. She said the conversation should be on regulation, not prohibition.

“We’re seeing the market become innovative. Entrepreneurs getting creative with the ways they can abide by the law and still provide their customers with the product they would like. What we’re looking at here is simply the result of supply and demand. We know there is a demand for cannabis products in the state of Texas. Unfortunately, our state continues to deprive legitimate business owners of the opportunity to sell these products in a regulated way, products that are tested that are labeled appropriately.”
— Heather Fazio, Texans for Responsible Marijuana Policy

DEA Statement:

Delta 8 THC was added to the controlled substances list in August 2020 on an interim basis while pending final disposition. As DEA is currently undergoing the rulemaking process regarding the implementation of the Agriculture Improvement Act of 2018 – which includes the scope of regulatory controls over marijuana, tetrahydrocannabinols, and other marijuana-related constituents – we would be unable to comment on an any impact in legality of tetrahydrocannabinols, Delta 8 included, until the process is complete. We are in the process of reviewing thousands of comments and do not speculate on what could happen as a result.

The exchange between Campion and Colin — “Maybe you want to get high” — became one of Colin’s most iconic media moments: radical honesty on mainstream television with expletive preserved by network. The piece balanced Colin’s unapologetic stance with Dr. Weaver’s medical caution and Heather Fazio’s regulatory advocacy, and full DEA statement documented federal ambiguity that allowed market to exist.

Feature: Houston CBD Shop Giving Away Free Products to Those Who Get COVID Vaccine — August 20, 2021

Source: ABC13 Houston (KTRK)
Headline: “Houston CBD shop giving away free products to those who get COVID vaccine”
Reporter: KTRK Staff
Published: Friday, August 20, 2021

Full Article Content

HOUSTON, Texas (KTRK) — A Houston CBD shop is offering a unique incentive to get people vaccinated.

According to an Instagram post published on Wednesday, OilWell CBD, which specializes in hemp-derived CBD and THC products, said it wants to give away 1,000 pieces of product to those who get vaccinated after Aug. 18.

The company is offering to give away 1,000 special edition caviar pre-rolls, which according to its website, is a THC-infused product coated with oils and hash kief, a more refined form of cannabis. OilWell sells these items for $34.99, according to its website.

The company said you must provide proof of vaccination along with a photo ID.

The giveaway will take place starting Monday at noon at HydroShack Hydroponics on West 20th Street in The Heights, which sells OilWell products.

“We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
— OilWell Instagram post

The company later posted another Instagram post saying it’s been in contact with the city of Houston to help more people get vaccinated.

“[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”
— OilWell follow-up Instagram post

The 2018 Farm Bill legalized hemp plants, which contain extremely low concentrations of the psychoactive compound Delta-9 THC. That’s the THC typically found in marijuana that gives users a high. Entrepreneurs are now extracting any compound they want from the hemp plants and have narrowed in on Delta-8 THC. Companies like OilWell are now making products such as edibles, tinctures, and smokables.

This feature documented OilWell’s most significant community health initiative — approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) donated to encourage COVID-19 vaccination. The pre-rolls were collaboration product: The Game x OilWell Cannabis Delta 8 Caviar Comet Rock Pre-Rolls. Giveaway hosted at same HydroShack Hydroponics retail partner featured in Delta-8 segment months earlier. OilWell’s coordination with city of Houston to amplify vaccination effort demonstrated company’s community orientation was not hypothetical — when public health crisis required action, company committed real product and real coordination with city government, with no political strings attached.

Feature: Texas Ban Over Once Legal Hemp Product Delta 8 Raises Questions Over Legality — October 19, 2021

Source: ABC13 Houston (KTRK)
Headline: “Texas’ ban over once legal hemp product, Delta 8, raises questions over legality”
Reporter: Shelley Childers
Published: Tuesday, October 19, 2021

Full Article Content

HOUSTON, Texas (KTRK) — Inside the Oil Well dispensary in southwest Houston, owner Colin Valencia said he has removed all of his Delta 8 products.

“It’s going to be a surprise to a lot of people.”
— Colin Valencia

It’s a surprise because when ABC13 met Valencia earlier this year, Delta 8 products were his best sellers.

“It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
— Colin Valencia

Delta 8 is a cannabinoid sold as edibles, tinctures, pills, topical ointment, you can smoke it and vape it. Most CBD dispensaries and vape stores sell it.

“We’ve heard of vets with PTSD who use these products for things like anxiety, dealing with stress and emotions. There’s also people who use these products for sleep regulation. Our association recently, during the state session, actually estimated that the Delta 8 market is around about $50 million in Texas.”
— Zachary Maxwell, Texas Hemp Growers

Delta 8 is derived from hemp cannabis. It took off after the 2018 Farm Bill legalized hemp production federally. It is a THC product and, up until last week, it was never explicitly listed on the state’s controlled substance list.

“A lot of the industry has been operating under the assumption that Delta 8 is legal or that it exists inside of this gray area, and unfortunately, as we are learning, this is not the case. These products have in fact been illegal since the beginning of this year.”
— Zachary Maxwell

On Oct. 15 the Texas Department of State Health Services posted an update on their Consumable Hemp Program page saying in part, “All other forms of THC, including Delta 8 in any concentration and Delta 9 exceeding 0.3%, are considered Schedule I controlled substances.”

“And if you’re caught with as much as a Delta 8 vape cartridge or even a package of gummies, you could be looking at a felony offense punishable up to two years in prison and a fine up as much as $10,000.”
— Zachary Maxwell

He says the state made no other formal notification to the more than 2,000 licensed CBD operators including Valencia, who has been trying to spread the word himself.

“So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
— Colin Valencia

ABC13 reached out to Texas DPS to find out if and how the state will enforce this-known ban. They were still awaiting a response.

ABC13 spoke with the Texas DSHS to ask about the updated verbiage on Delta 8. A spokesperson says Delta 8 has always been illegal because it is a THC cannabinoid. She could not speak to how the Delta 8 market was allowed to publicly blossom and thrive while being considered illegal. She told ABC13 that the hemp industry asked DSHS for clarification on its legality which prompted the announcement last Friday.

While both men worry for the small businesses who rely on Delta 8 products for the majority of sales, they remain optimistic about the future of cannabis in Texas.

“It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”
— Colin Valencia

This feature captures defining moment in OilWell’s story. Just two months after COVID vaccine giveaway, legal landscape shifted dramatically overnight. Shelley Childers went directly to OilWell dispensary and found Colin had already removed all Delta-8 products from shelves — proactively, before enforcement began, before most of industry even knew change had happened. Colin had been trying to spread word himself to other operators who were unknowingly shipping what had overnight become Schedule I narcotics. Zachary Maxwell’s context — veterans with PTSD, $50 million Texas market, felony penalties for single vape cartridge — made stakes viscerally clear. Texas DSHS told ABC13 that Delta-8 “has always been illegal” but could not explain how market had been “allowed to publicly blossom and thrive while being considered illegal.” Willingness to absorb major revenue loss, act ethically ahead of enforcement, and position company as expert guide for industry in crisis rather than victim of regulation — that is OilWell’s character.

Feature: Experts Weigh In on Why Texas Won’t See Impact in Accordance with Biden’s Pardon Announcement — October 7, 2022

Source: ABC13 Houston (KTRK)
Headline: “Experts weigh in on why Texas won’t see impact in accordance with Biden’s pardon announcement”
Reporter: Nick Natario
Published: Friday, October 7, 2022

Full Article Content

HOUSTON, Texas (KTRK) — President Joe Biden is planning to pardon thousands of Americans convicted of simple possession of marijuana, but Texas will not see much of an impact.

The owners of Oilwell Cannabis are preparing to debut their latest idea: A vending machine that will be filled with legal cannabidiol, or CBD, products.

The shop owner, Collin Valencia, has previously faced charges for marijuana possession.

“You face challenges with housing, loans, and banking, I mean with about everything.”
— Colin Valencia

Soon, select others won’t face those challenges after the president’s announcement.

“I would love to see people not get hurt for this anymore.”
— Colin Valencia

The pardon doesn’t impact Valencia. As legal expert Steve Shellist explains, this will only apply to certain federal convictions.

“If someone is currently stripped of rights via a state prosecution or a state conviction, they’re going to get no relief from this.”
— Steve Shellist, legal expert

He said a pardon allows people to carry a gun or avoid deportation.

“It reinstates rights that were stripped away, but it does not remove it from their record.”
— Steve Shellist

The pardon applies to about 6,500 people. Experts at Rice University said that there were 300,000 marijuana-related arrests at the state level last year. President Biden urged governors to do the same with state charges.

A spokesperson for Governor Greg Abbott sent ABC13 a statement that read:

“Texas is not in the habit of taking criminal justice advice from the leader of the defund police party and someone who has overseen a criminal justice system run amuck with cashless bail and a revolving door for violent criminals.”
— Governor Greg Abbott’s spokesperson

On social media, Abbott’s opponent Beto O’Rourke said, “When I’m governor, we will finally legalize marijuana in Texas and expunge the records of those arrested for marijuana possession.”

“Governors do not have the power to pass legislation unilaterally. It has to go through the Texas Legislature, and the Texas legislature for at least the next two or four years is going to have a Republican majority.”
— Mark Jones, Rice University political science professor

Don’t expect to see marijuana legalization in the upcoming session. However, it doesn’t mean the matter won’t be discussed.

“The most we’ll see in 2023 is decriminalizing marijuana and medical marijuana. We’re not going to see legalization. That’s for sure.”
— Mark Jones

This feature brought most personal dimension of Colin’s story into public view. Article opened with OilWell CBD vending machine debut — retail innovation extending product accessibility beyond traditional dispensary hours — then revealed Colin has previously faced charges for marijuana possession. That personal history transforms entire media record. Every feature, every quote about therapy, education, not selling snake oil — all carry additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization. Political context (300,000 state arrests vs. 6,500 pardons, Abbott vs. O’Rourke, Mark Jones’s analysis) captured gap between federal gestures and Texas reality. Colin is not outside entrepreneur who saw business opportunity. He is someone who lived consequences and built legal business to prove industry could operate with integrity, transparency, and community benefit.

Feature: Marijuana Industry Getting Creative as Texas Laws Continue to Change — April 21, 2023

Source: ABC13 Houston (KTRK)
Headline: “‘I want it to be legalized’: Marijuana industry getting creative as Texas laws continue to change”
Reporter: Nick Natario
Published: Friday, April 21, 2023

Full Article Content

HOUSTON, Texas (KTRK) — On April 20, some Texas lawmakers and those in the marijuana industry are celebrating as changes could be coming with the drug.

The cannabis industry has changed in Texas, and new laws have allowed those in the industry to get creative.

“I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
— Oilwell Cannabis owner Colin Valencia

Valencia grows something that looks like marijuana, but he says it’s not illegal. It’s hemp — a product the state allows and one that gives him the ability to create all kinds of products.

“Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”
— Colin Valencia

As far as legal marijuana, it’s still restrictive in Texas. To use it, marijuana needs to be prescribed. There are currently around 50,000 Texans registered, but experts say only about 10,000 actively use medical marijuana.

“By comparison to Florida, which is two-thirds the size of Texas, they have 20 million people, and we have 30 million people, and they have 700,000 patients.”
— Nico Richardson, Texas Original CEO

But that number could change soon. Texas lawmakers are considering a bill (HB1805) to expand who could gain access.

“Would rather dramatically increase the size of the CUP. The largest constituency of patients not being treated with medical cannabis today is chronic pain.”
— Nico Richardson

The bill passed the House and is heading to the Senate. It would also change how the drug is dosed to line up with other medical treatments.

“If you were to treat a headache with 400 milligrams of Advil and there was a one percent concentration cap, you would be using 20 to 40 Advil pills every time you had a headache.”
— Nico Richardson

While it’s not legalization, in other states, it’s had an impact, especially with money. The Marijuana Policy Project said in 2021 alone, $3.7 billion was generated in taxes in the states where marijuana is legal.

The CDC urges caution, saying more studies need to be done because the drug could impact your brain, lungs, and unborn children.

The most recent ABC13 feature, published day after 4/20, completes four-year arc. Natario showed Valencia growing hemp and explained it was legal. Colin’s “Renaissance” framing reframed present as opportunity rather than waiting. Nico Richardson’s comparison (Texas 10,000 active patients vs. Florida 700,000 with two-thirds population) and his Advil analogy for dosing caps provided industry context. HB1805’s passage through House and $3.7 billion tax revenue figure from legal states gave story national scope. From September 2019 CBD business profile through Delta-8 boom and bust, COVID community initiative, personal revelation of cannabis conviction history, and now “Renaissance” framing — Colin Valencia’s media trajectory mirrors trajectory of legal cannabis in Texas itself.

Complete Index of All Colin Valencia Quotes Across All ABC13 Features

Chronological order:

September 15, 2019 (CBD Business Boom):

1. “It’s a lot of educating people, but not over-promising people. I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

March 22, 2021 (Decriminalization/Jonathan Pina):
2. “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

May 24, 2021 (Delta-8 THC “Legal Weed”):
3. “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

August 20, 2021 (COVID Vaccine Giveaway):
4. “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”
5. “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

October 19, 2021 (Delta-8 Ban):
6. “It’s going to be a surprise to a lot of people.”
7. “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.”
8. “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”
9. “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

October 7, 2022 (Biden Marijuana Pardon):
10. “You face challenges with housing, loans, and banking, I mean with about everything.”
11. “I would love to see people not get hurt for this anymore.”

April 21, 2023 (Texas Marijuana Laws 4/20):
12. “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.”
13. “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

Key Facts and Details Extracted from Media Record

About Colin Valencia and OilWell Cannabis:

• Colin Valencia is owner of OilWell Cannabis (also referred to as OilWell CBD in earlier articles)
• He has previously faced charges for marijuana possession (revealed in October 2022 Biden pardon feature)
• OilWell dispensary located in southwest Houston
• OilWell specializes in hemp-derived CBD and THC products
• OilWell was described as local wholesaler in 2019 (earliest feature)
• By 2022, OilWell was preparing to debut CBD vending machine (Biden pardon feature)
• OilWell products sold at HydroShack Hydroponics on West 20th Street in The Heights
• OilWell partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls (COVID vaccine feature)
• OilWell gave a lift to Jonathan Pina’s High Maintenance Edibles mobile vendor concept (decriminalization feature)
• OilWell gave away 1,000 special edition caviar pre-rolls (valued at $34.99 each = ~$35,000 in product) to encourage COVID vaccination
• OilWell contacted city of Houston to help coordinate vaccination efforts
• Colin proactively removed all Delta-8 products from shelves when ban announced and tried to spread word to other operators unknowingly shipping Schedule I narcotics

ABC13 Reporters Who Covered OilWell:

1. Tom Abrahams — September 2019 and March 2021
2. Steve Campion — May 2021
3. KTRK Staff — August 2021
4. Shelley Childers — October 2021
5. Nick Natario — October 2022 and April 2023

The Through-Line — What the Media Record Reveals

Taken together, these seven ABC13 features and one YouTube clip tell story no single article could capture.

Consistency across years. Colin Valencia appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. Cannabis industry in Texas changed dramatically during those years — legal CBD went from gray area to booming business, Delta-8 went from unknown to $50 million market to Schedule I overnight, president pardoned federal marijuana convictions, and state legislators debated medical expansion. Through every shift, ABC13 returned to Colin as primary source.

Breadth of expertise. Features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range across that many segments.

Community action. COVID vaccine giveaway — $35,000 in product, coordination with city government, no political strings — is documented evidence of community-first philosophy described in About OilWell section. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. October 2022 revelation that Colin has personal marijuana conviction history transforms entire media record. Every feature, every quote about therapy, education, not selling snake oil — all carry additional weight when you understand person saying it has personally experienced consequences of cannabis criminalization.

Evolution of language. In 2019, ABC13 called business “OilWell CBD, a local wholesaler.” By 2021, reports described OilWell Cannabis as dispensary and featured Colin as industry authority. By 2023, Colin was explaining industry dynamics and legal strategy on camera with confidence of sector leader. Media record tracks growth of both business and founder’s public role.

These features are not marketing materials. They are independently produced, editorially controlled news segments from major-market ABC affiliate that repeatedly identified Colin Valencia as most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased — it can only be earned.

General Knowledge

Research Method and Evidence Weighting

This section prioritizes sources in following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data sparse. That weighting matters because evidence base is not evenly distributed. Of compounds listed, CBD and delta-9 THC have strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH and Related Sources

• NCCIH states strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss indications in HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still early-stage.
• NCCIH emphasizes FDA has not approved cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination/labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns over-the-counter CBD products may differ from labels and CBD itself associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoids

CBD

• Evidence profile: strongest human evidence in current formula set, especially when studied as purified product.
• Best supported: purified CBD has most credible human evidence in seizure disorders, clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety: 2024 systematic review and meta-analysis of 316 participants across eight articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials needed.
• Pain: 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality/consistency limiting confidence.
• Sleep: 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and few objective sleep assessments.
• Safety: 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy settings. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions.
• Bottom line: CBD is most evidence-developed nonintoxicating cannabinoid, but even here strong evidence concentrated in few specific indications rather than broad wellness claims.

CBG

• Evidence profile: mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is biosynthetic precursor to several major cannabinoids, appears pharmacologically distinct from THC and CBD. Review literature describes interactions spanning cannabinoid receptors plus alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established.
• Potential areas: reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity, but primarily pharmacology-led hypotheses or preclinical findings.
• Caution: 2021 pharmacology review notes CBG already being sold commercially while evidence base remains thin, meaning claims frequently outrun science.
• Bottom line: CBG is serious research topic, but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic.

Delta-8 THC

• Evidence profile: pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC.
• Comparative pharmacology: 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is partial CB1 agonist with cannabimimetic activity in animals/humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity.
• Public health: 2023 scoping review found much of delta-8 evidence base still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Review also noted reports of adverse consequences and emphasized regulatory/product-quality concerns.
• Manufacturing: recent chemistry/pharmacology review reinforces commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is why product-byproduct and lab-testing questions matter.
• Bottom line: delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa

• Evidence profile: important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is acidic precursor of THC, may represent very large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can change over time during storage/processing.
• Psychoactivity: major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated.
• Research status: in vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but not equivalent to established human outcomes.
• Bottom line: THCa best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC.

Delta-9 THC

• Evidence profile: strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden.
• Institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage.
• Pain: 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Pharmacokinetics: classic review literature remains useful: inhaled THC produces effects within seconds-minutes, peaks roughly 15-30 minutes, tapers over few hours; oral THC has later onset, later peak, longer duration, which matters for both benefit and overconsumption risk.
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.
• Broader safety: institutional/review literature also describe anxiety/panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, vape-related lung-injury concerns.
• Bottom line: delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities.

CBN

• Evidence profile: weak human evidence; marketing has clearly moved ahead of data.
• What marketed for: sleep and sedation. Reputation widespread, but clinical support far thinner than market suggests.
• Best direct review: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims.
• Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still doesn’t match scale of real-world use, and need for better-designed, adequately powered trials remains substantial.
• Chemical context: downstream cannabinoid degradation pathways matter; review literature on THCa notes THC can further degrade toward CBN under certain conditions, explaining why CBN often discussed in aging/oxidized cannabis chemistry contexts.
• Bottom line: CBN is one of clearest examples where cultural reputation is stronger than current clinical evidence base.

CBC

• Evidence profile: emerging, intriguing, still overwhelmingly preclinical or review-based.
• Pharmacology: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• Older literature: review literature summarizing CBC in animal/in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological or antiproliferative relevance, but signals not yet strong evidence for patient-facing claims.
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products already being sold despite little evidence establishing clinical efficacy or safety.
• Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives.

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: largely review and preclinical, with useful safety literature.
• Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities, but overwhelming share of claims comes from nonhuman or non-cannabis literature.
• Safety note: limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature.
• Bottom line: limonene biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans.

Myrcene

• Evidence profile: mostly preclinical, very limited human evidence.
• Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and discusses possible mechanisms, but explicitly states human studies lacking.
• Interpretation caution: myrcene often invoked in consumer language as if proven sedating terpene that explains couch-lock or sleep effects — stronger claim than human evidence currently supports.
• Bottom line: myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene

• Evidence profile: among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation limited.
• Bottom line: beta-caryophyllene arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed.

Pinene

• Evidence profile: promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking.
• Interpretation caution: claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.
• Bottom line: pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool

• Evidence profile: similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: linalool repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological/psychiatric contexts, while still emphasizing lack of robust human trials.
• Additional literature: separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story.
• Safety note: as with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.
• Bottom line: linalool scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene

• Evidence profile: translationally interesting, but still early.
• Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.
• Bottom line: humulene one of more interesting terpene research targets, but remains far from clinically settled.

Terpinolene

• Evidence profile: one of least clinically characterized terpenes in this file.
• Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.
• Bottom line: terpinolene biologically interesting, but among listed terpenes remains especially underdeveloped clinically.

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error in cannabis writing is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
• For THCa in particular, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.
• Overstatement: myrcene is proven human sedative that reliably explains couch-lock.
  More accurate: myrcene has plausible preclinical bioactivity, but direct human proof for common claim limited.
• Overstatement: terpenes in general have proven entourage effects in patients.
  More accurate: entourage hypotheses influential and worth studying, but robust clinical proof remains limited and highly compound-specific.
• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa to THC, changing effective exposure.
• Overstatement: delta-8 THC is safe because hemp-derived.
  More accurate: delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for The Formulas in This Document

• Most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene — pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

Legal Disclaimer and Safety Information

Age Requirement: All OilWell RSO products are available only to customers age 21 and older.

THC Content Compliance: OilWell RSO products contain less than 0.3% delta-9 THC by dry weight and are compliant with the 2018 Farm Bill. All cannabinoids are hemp-derived.

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns.

Safety Warnings: May cause drowsiness or impairment. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Use responsibly. Keep out of reach of children and pets. Store in a cool, dry place away from direct sunlight.

Legal Responsibility: Customers are responsible for understanding and complying with all local, state, and federal laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. Montana customers should verify state law compliance before decarboxylating THCa. International customers accept all customs and legal responsibility. OilWell assumes no legal liability for customer’s use or decarboxylation decisions.

Product Integrity: All OilWell products are manufactured in a licensed facility using Good Manufacturing Practices (GMP). Third-party lab testing verifies potency, purity, and safety. Certificates of Analysis (COAs) are available for every batch.

Contact Information:
OilWell Cannabis
810 Richmond Avenue
Houston, TX 77006
Phone: (832) 416-2816
Email: [email protected]
Website: https://oilwellcbd.com/

Hours:
Monday-Thursday: 10:00 AM – 7:00 PM
Friday-Saturday: 10:00 AM – 10:00 PM
Sunday: 10:00 AM – 4:00 PM

Shipping to Montana: All orders placed by Montana residents will be processed within 1-2 business days and shipped via USPS Priority Mail or UPS Ground, depending on address. Transit time to Montana typically 3-5 business days. Tracking information provided via email once order ships. All packages discreetly labeled with no cannabis branding visible externally.

Community Commitment: OilWell Cannabis is committed to supporting Montana communities. Whether you’re a veteran in Billings, a cancer patient in Missoula, a chronic pain sufferer in Bozeman, or anyone else seeking alternatives to conventional pharmaceuticals, we see you. Our Montana customers receive same level of transparency, quality, and evidence-based education that earned us recognition in Houston. We understand Montana values — independence, self-reliance, and practical solutions — and our open-source philosophy aligns with that spirit.

Final Note for Montana Readers: The information in this document represents the most comprehensive, honest, and scientifically grounded RSO education available anywhere. We’ve provided complete formulas, full research citations, and unflinching assessment of what evidence supports versus what remains uncertain. For Montanans facing serious health challenges, we hope this provides the foundation for informed decision-making and meaningful conversations with your healthcare providers. For those who choose to try our products, we commit to delivering the same quality and integrity that saved Bentley and helped Colin rebuild his life. For those who use our open-source formulas to make your own, we honor that choice as truest expression of Rick Simpson’s original vision.